You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: August 23, 2024

LOZOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lozol patents expire, and what generic alternatives are available?

Lozol is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOZOL is indapamide. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the indapamide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lozol

A generic version of LOZOL was approved as indapamide by ANI PHARMS on July 27th, 1995.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOZOL?
  • What are the global sales for LOZOL?
  • What is Average Wholesale Price for LOZOL?
Summary for LOZOL
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 114
Patent Applications: 3,907
DailyMed Link:LOZOL at DailyMed
Drug patent expirations by year for LOZOL

US Patents and Regulatory Information for LOZOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LOZOL indapamide TABLET;ORAL 018538-002 Apr 29, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us LOZOL indapamide TABLET;ORAL 018538-001 Jul 6, 1983 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LOZOL

See the table below for patents covering LOZOL around the world.

Country Patent Number Title Estimated Expiration
Spain 364421 ⤷  Sign Up
Sweden 334887 ⤷  Sign Up
Italy 8049196 ⤷  Sign Up
France 2003311 ⤷  Sign Up
United Kingdom 1203691 ⤷  Sign Up
Netherlands 6903421 ⤷  Sign Up
Switzerland 507940 Procédé de préparation de nouveaux dérivés de la N-amino indoline disubstituée ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.